Erasca Inc. (ERAS)
Erasca Inc. (ERAS) Stock Price, Analysis & Data
| Bid | 13.59 |
| Market Cap | 6.5B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -277.02M |
| Beta | 0.65 |
| EPS (ttm) | -0.96 |
| PE Ratio (ttm) | n/a |
| Forward PE | -32.55 |
| P/B (ttm) | 14.68 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | 23.61 |
| Volume | 3,609,080 |
| Avg. Volume (20D) | 4,995,624 |
| Open | 18.43 |
| Previous Close | 18.31 |
| Day's Range | 18.27 - 19.22 |
| 52-Week Range | 1.33 - 24.28 |
| Analyst | Buy |
| Price Target | 23 (23.79%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...
Financial Performance
In 2025, Erasca's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -124.55M, a decrease of -22.95%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for ERAS stock is "Buy". The 12-month stock price forecast is 23, which is upside of 23.79% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
